News

This episode highlights the importance of closing persistent gaps in skin cancer prevention and awareness for patients with skin of color.

Goodyear explores how the medical community often downplays this risk and why it's time for a more transparent, patient-first conversation.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

This Q&A interview highlights the broader implications of the phase 3b TOGETHER-PsO trial for ixekizumab and tirzepatide in managing psoriatic disease.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

This interview highlights recent phase 3b data from the TOGETHER-PsO trial on ixekizumab and tirzepatide for psoriasis and obesity or overweight.

Miedema highlights the shortcomings of current technology and medication for what is among the US’s fastest-growing and most devastating conditions.

Jeffrey Thiboutot, MD, discussed efficacy advantages seen in the trial at ATS 2026.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.

This segment of a Q&A interview with Kilian Eyerich, MD, PhD, highlights the signficance of the LumiNE phase 3 study on lebrikizumab.

Joshua Barrios, PhD, and Geoffrey Tison, MD, MSc, discuss their new AI echo’s comparative superiority in identifying cardiovascular disease.

A new phase 3 study is evaluating lebrikizumab in at least 270 patients with nummular eczema over 48 weeks.

Wilcox discusses the recent HFSA statement aiming to identify the unique characteristics of HFmrEF and define an alternative treatment pathway.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Retatrutide successfully reduced body weight versus placebo in adults with obesity or overweight in topline phase 3 TRIUMPH-1 results.

Klaus Friedrich Rabe, MD, PhD, spoke at ATS about the mixed phase 3 AERIFY trial findings on itepekimab, an anti–IL-33 monoclonal antibody, in COPD.

At ATS, Klaus Friedrich Rabe, MD, PhD, discussed phase 3 data on itepekimab in former smokers with chronic obstructive pulmonary disease (COPD).

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover more of the upcoming news releases announced for ADA 2026.

Experts unpack new asthma/COPD biologics, eosinophil+FeNO targeting, twice-yearly depemokimab switching, and payer hurdles in 2026 care.

Deepak Bhatt, MD, MPH, MBA, discusses his recent presentation at the ASPC 2026 Virtual Imaging Symposium and how plaque imaging can change the MI landscape.

At ATS 2026, Vallerie McLaughlin, MD discusses ADVANCE OUTCOMES showing ralinepag reduced PAH clinical worsening risk by 55% in pretreated patients.

This interview at ATS highlights key takeaways regarding new phase 3 data on AD109 for obstructive sleep apnea (OSA).

Results from the phase 3 TETON-1 study presented at ATS 2026 showed inhaled treprostinil preserved lung function and reduced clinical worsening risk in IPF.

At ATS 2026, pooled phase 3 data showed mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the presentations that they’re looking forward to at ADA 2026.

This interview at ATS 2026 highlights notable findings on the once-nightly oral pill, AD109, in obstructive sleep apnea (OSA).

At ATS 2026, phase 3b ENCORE findings showed amikacin liposome inhalation suspension achieved high culture conversion rates in newly diagnosed MAC lung disease.

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.